tetano
Editor, Senior Moderator
Vaccine
. 2025 Aug 2:62:127566.
doi: 10.1016/j.vaccine.2025.127566. Online ahead of print. Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis
Rong Liu[SUP] 1 [/SUP], Anushka Patel[SUP] 2 [/SUP], Hueiming Liu[SUP] 3 [/SUP], Xin Du[SUP] 4 [/SUP], Gian Luca Di Tanna[SUP] 5 [/SUP], Stephen Jan[SUP] 6 [/SUP], Emily R Atkins[SUP] 7 [/SUP]
Affiliations
Introduction: People with heart failure (HF) are at higher risk of experiencing severe cardiac complications including hospitalization and death, from seasonal influenza infection. In addition to preventing influenza infections, influenza vaccination's effect on preventing hospitalization and death may impact its cost-effectiveness among people with HF. Moreover, uncertainty of its cost-effectiveness has been reported as a barrier for public funding of influenza vaccination in such populations.
Methods: We conducted a cost-effectiveness analysis of a program of seasonal influenza vaccination for patients with HF upon discharge from hospital, compared to usual care, in China. The analysis involved four-health-state Markov model in which we modelled a hypothetical cohort of patients discharged alive with HF from county-level hospital cardiology wards in Henan Province, China. The intervention is provision of free influenza vaccine on the day of hospital discharge, with treating physician's recommendation, and convenient Point of Vaccination (PoV) within the hospital. The comparator is usual care, which generally would be advice at discharge to attend a community based PoV. We performed a cost-effectiveness analysis from a health system perspective with a one-year time horizon. Outcomes were cost, influenza-like-illness (ILI), readmission, death, and quality-adjusted life year (QALY).
Findings: The intervention strategy had an overall cost of US$ 2,456 per person per year compared to the cost of $2,899 per person per year with usual care. The intervention strategy resulted in 0.57 QALYs per person per year, compared to 0.53 QALYs under usual care. The intervention strategy was dominant over usual care - with estimated cost savings of $443 and 0.03 higher QALYs per patient discharged alive over 12 months. Overall, implementing the influenza vaccination strategy in a cohort of 1,000 individuals results in 28 less ILI cases, 164 fewer hospitalizations, and 44 fewer deaths per 1,000 patients discharged alive, and overall cost savings of $443,000 over this period. In one-way sensitivity analysis, the intervention strategy remains robustly cost-effective across a wide range of assumptions. The probability of intervention strategy being cost-effective is 84 %, at the willingness-to-pay threshold of $37,668 per QALY.
Conclusion: Although very few hospital wards routinely offer influenza vaccination for patients on discharge, doing so has the potential to both save lives and reduce government health care expenditure.
Trial registration: ChiCTR.org.cn: ChiCTR2000039081.
Keywords: Cardiovascular disease; Cost-effectiveness; Economic evaluation; Influenza vaccine.
. 2025 Aug 2:62:127566.
doi: 10.1016/j.vaccine.2025.127566. Online ahead of print. Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis
Rong Liu[SUP] 1 [/SUP], Anushka Patel[SUP] 2 [/SUP], Hueiming Liu[SUP] 3 [/SUP], Xin Du[SUP] 4 [/SUP], Gian Luca Di Tanna[SUP] 5 [/SUP], Stephen Jan[SUP] 6 [/SUP], Emily R Atkins[SUP] 7 [/SUP]
Affiliations
- PMID: 40753672
- DOI: 10.1016/j.vaccine.2025.127566
Introduction: People with heart failure (HF) are at higher risk of experiencing severe cardiac complications including hospitalization and death, from seasonal influenza infection. In addition to preventing influenza infections, influenza vaccination's effect on preventing hospitalization and death may impact its cost-effectiveness among people with HF. Moreover, uncertainty of its cost-effectiveness has been reported as a barrier for public funding of influenza vaccination in such populations.
Methods: We conducted a cost-effectiveness analysis of a program of seasonal influenza vaccination for patients with HF upon discharge from hospital, compared to usual care, in China. The analysis involved four-health-state Markov model in which we modelled a hypothetical cohort of patients discharged alive with HF from county-level hospital cardiology wards in Henan Province, China. The intervention is provision of free influenza vaccine on the day of hospital discharge, with treating physician's recommendation, and convenient Point of Vaccination (PoV) within the hospital. The comparator is usual care, which generally would be advice at discharge to attend a community based PoV. We performed a cost-effectiveness analysis from a health system perspective with a one-year time horizon. Outcomes were cost, influenza-like-illness (ILI), readmission, death, and quality-adjusted life year (QALY).
Findings: The intervention strategy had an overall cost of US$ 2,456 per person per year compared to the cost of $2,899 per person per year with usual care. The intervention strategy resulted in 0.57 QALYs per person per year, compared to 0.53 QALYs under usual care. The intervention strategy was dominant over usual care - with estimated cost savings of $443 and 0.03 higher QALYs per patient discharged alive over 12 months. Overall, implementing the influenza vaccination strategy in a cohort of 1,000 individuals results in 28 less ILI cases, 164 fewer hospitalizations, and 44 fewer deaths per 1,000 patients discharged alive, and overall cost savings of $443,000 over this period. In one-way sensitivity analysis, the intervention strategy remains robustly cost-effective across a wide range of assumptions. The probability of intervention strategy being cost-effective is 84 %, at the willingness-to-pay threshold of $37,668 per QALY.
Conclusion: Although very few hospital wards routinely offer influenza vaccination for patients on discharge, doing so has the potential to both save lives and reduce government health care expenditure.
Trial registration: ChiCTR.org.cn: ChiCTR2000039081.
Keywords: Cardiovascular disease; Cost-effectiveness; Economic evaluation; Influenza vaccine.